STERIS plc STE
HEALTHCARE · MEDICAL DEVICESi
Market dataready · fetched 2026-11-12T15:19:49.795Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:17:46.188282424Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T15:19:49.370900+00:00
STERIS plc options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 267.23 | 34.3% | 5.5% | 244.28 | 32.2% | 4.7% |
| 25Δ | 264.63 | 32.8% | 4.6% | 246.54 | 31.8% | 4.0% |
| 30Δ | 262.03 | 31.3% | 3.7% | 248.80 | 31.4% | 3.3% |
| 35Δ | 259.67 | 30.2% | 3.0% | 250.70 | 31.1% | 2.7% |
| 40Δ | 258.19 | 30.2% | 2.7% | 252.18 | 30.8% | 2.4% |
| 45Δ | 256.71 | 30.3% | 2.4% | 253.66 | 30.6% | 2.1% |
| 50Δ | 255.23 | 30.3% | 2.1% | 255.14 | 30.4% | 1.8% |
| 55Δ | 253.75 | 30.4% | 1.8% | 256.62 | 30.1% | 1.5% |
| 60Δ | 252.27 | 30.4% | 1.5% | 258.10 | 29.9% | 1.2% |
| 65Δ | 250.79 | 30.5% | 1.2% | 259.58 | 29.7% | 0.9% |
| 70Δ | 248.91 | 30.9% | 1.0% | 261.61 | 29.9% | 0.7% |
| 75Δ | 246.57 | 31.7% | 0.8% | 263.85 | 30.3% | 0.6% |
| 80Δ | 244.23 | 32.5% | 0.7% | 266.09 | 30.7% | 0.4% |
20Δ
- Pseudo strike
- 267.23
- IV
- 34.3%
- B/E move
- 5.5%
- Pseudo strike
- 244.28
- IV
- 32.2%
- B/E move
- 4.7%
25Δ
- Pseudo strike
- 264.63
- IV
- 32.8%
- B/E move
- 4.6%
- Pseudo strike
- 246.54
- IV
- 31.8%
- B/E move
- 4.0%
30Δ
- Pseudo strike
- 262.03
- IV
- 31.3%
- B/E move
- 3.7%
- Pseudo strike
- 248.80
- IV
- 31.4%
- B/E move
- 3.3%
35Δ
- Pseudo strike
- 259.67
- IV
- 30.2%
- B/E move
- 3.0%
- Pseudo strike
- 250.70
- IV
- 31.1%
- B/E move
- 2.7%
40Δ
- Pseudo strike
- 258.19
- IV
- 30.2%
- B/E move
- 2.7%
- Pseudo strike
- 252.18
- IV
- 30.8%
- B/E move
- 2.4%
45Δ
- Pseudo strike
- 256.71
- IV
- 30.3%
- B/E move
- 2.4%
- Pseudo strike
- 253.66
- IV
- 30.6%
- B/E move
- 2.1%
50Δ
- Pseudo strike
- 255.23
- IV
- 30.3%
- B/E move
- 2.1%
- Pseudo strike
- 255.14
- IV
- 30.4%
- B/E move
- 1.8%
55Δ
- Pseudo strike
- 253.75
- IV
- 30.4%
- B/E move
- 1.8%
- Pseudo strike
- 256.62
- IV
- 30.1%
- B/E move
- 1.5%
60Δ
- Pseudo strike
- 252.27
- IV
- 30.4%
- B/E move
- 1.5%
- Pseudo strike
- 258.10
- IV
- 29.9%
- B/E move
- 1.2%
65Δ
- Pseudo strike
- 250.79
- IV
- 30.5%
- B/E move
- 1.2%
- Pseudo strike
- 259.58
- IV
- 29.7%
- B/E move
- 0.9%
70Δ
- Pseudo strike
- 248.91
- IV
- 30.9%
- B/E move
- 1.0%
- Pseudo strike
- 261.61
- IV
- 29.9%
- B/E move
- 0.7%
75Δ
- Pseudo strike
- 246.57
- IV
- 31.7%
- B/E move
- 0.8%
- Pseudo strike
- 263.85
- IV
- 30.3%
- B/E move
- 0.6%
80Δ
- Pseudo strike
- 244.23
- IV
- 32.5%
- B/E move
- 0.7%
- Pseudo strike
- 266.09
- IV
- 30.7%
- B/E move
- 0.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 27.46% | |
| 27.70% | |
| 27.83% | |
| 28.04% | |
| 28.62% | |
| 29.87% | |
| 30.10% | |
| 31.75% | |
| 30.55% | |
| 31.10% |
Medical Devices
STIM
Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and…
More →SYK
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and…
More →TCMD
Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The…
More →TLSI
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems,…
More →TMCI
Description unavailable
More →TMDX
Description unavailable
More →